Anzeige
Mehr »
Donnerstag, 04.09.2025 - Börsentäglich über 12.000 News
Set to Action: Q-Gold vor drastischer Neubewertung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JLMD | ISIN: US03168L1052 | Ticker-Symbol: 2DT
Tradegate
02.09.25 | 17:07
8,250 Euro
+0,61 % +0,050
1-Jahres-Chart
AMNEAL PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
AMNEAL PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
8,2508,40023:01
8,1008,30022:00

Aktuelle News zur AMNEAL PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22:18FDA approves Amneal's generic risperidone for schizophrenia treatment1
22:10FDA erteilt Amneal Zulassung für Risperidon-Generikum zur Schizophrenie-Behandlung4
22:06Amneal Pharmaceuticals, Inc.: Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension1
16:10Amneal gets FDA warning letter tied to prior recalls of antibacterial products2
07.08.Amneal Pharmaceuticals, Inc. - 10-Q, Quarterly Report1
05.08.Amneal raises 2025 guidance and targets $300M-$500M peak CREXONT sales as new launches accelerate1
AMNEAL PHARMACEUTICALS Aktie jetzt für 0€ handeln
05.08.Amneal Pharmaceuticals, Inc. Q2 Profit Increases, Beats Estimates-
05.08.Amneal Pharmaceuticals, Inc.: Amneal Reports Second Quarter 2025 Financial Results186? Q2 2025 Net Revenue of $725 million; GAAP Net Income of $22 million; Diluted Income per Share of $0.07 ?? Adjusted EBITDA of $184 million; Adjusted Diluted EPS of $0.25 ?? Raising 2025 Full Year...
► Artikel lesen
04.08.A Peek at Amneal Pharmaceuticals' Future Earnings5
04.08.Amneal Pharmaceuticals Q2 2025 Earnings Preview2
01.08.Amneal Pharmaceuticals, Inc. - 8-K, Current Report1
21.07.Amneal Pharmaceuticals announces unaudited preliminary Q2 revenue between $720M and $730M4
21.07.Amneal seeks to borrow $1.8 billion in new term loans, offers notes2
21.07.Amneal reports 3% revenue growth in Q2, advances deleveraging2
21.07.Amneal plant Refinanzierung über neue Kredite und Anleihen im Milliardenwert5
21.07.Amneal Pharmaceuticals, Inc.: Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results838- Results Reflect Continued Financial Strength and Deleveraging - BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today...
► Artikel lesen
21.07.Amneal Pharmaceuticals, Inc.: Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 20322
21.07.Amneal Pharmaceuticals, Inc. - 8-K, Current Report1
12.07.Amneal Pharmaceuticals (AMRX) Announces FDA Approval of Prednisolone Acetate Ophthalmic Suspension5
09.07.Amneal Pharmaceuticals, Inc.: Amneal to Report Second Quarter 2025 Results on August 5, 20253
Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1